Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All tixagevimab/cilgavimab..
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchTixagevimab/cilgavimabTixagev../c.. (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 59% Improvement Relative Risk Case 25% Tixagevimab/c..  Najjar-Debbiny et al.  Prophylaxis Is prophylaxis with tixagevimab/cilgavimab beneficial for COVID-19? Retrospective 3,515 patients in Israel Lower hospitalization (p=0.023) and fewer cases (p=0.025) c19early.org Najjar-Debbiny et al., Clinical Infect.., Oct 2022 Favors tixagevimab/ci.. Favors control

Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis

Najjar-Debbiny et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac855
Oct 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
37th treatment shown to reduce risk in May 2022
 
*, now known with p = 0.000013 from 16 studies, recognized in 30 countries. Efficacy is variant dependent.
Lower risk for mortality, hospitalization, and cases.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective 732 immunocompromised patients in Israel treated with tixagevimab/cilgavimab, and 2,812 matched controls, showing significantly lower cases and hospitalization with treatment.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2.75.2, BA.4.6, BQ.1.1 Planas, BA.5, BA.2.75, XBB Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
risk of hospitalization, 59.0% lower, HR 0.41, p = 0.02, treatment 72 of 703 (10.2%), control 377 of 2,812 (13.4%), Cox proportional hazards.
risk of case, 25.0% lower, HR 0.75, p = 0.03, treatment 72 of 703 (10.2%), control 377 of 2,812 (13.4%), NNT 32, Cox proportional hazards.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Najjar-Debbiny et al., 31 Oct 2022, retrospective, Israel, peer-reviewed, 5 authors. Contact: ronzana@clalit.org.il, ronza.najjar@gmail.com.
This PaperTixagev../c..All
Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis
MD Ronza Najjar-Debbiny, MD Naomi Gronich, MD Gabriel Weber, MPH Nili Stein, MD, MPH Walid Saliba
Background: Tixagevimab and Cilgavimab, a combined monoclonal antibody (Evusheld) was granted emergency use authorization for SARS-CoV-2 preexposure prophylaxis in individuals with moderate to severe immunocompromising condition. In this study we used population-based real-world data to evaluate the effectiveness of Evusheld in immunocompromised patients. Methods: Using the computerized database of the largest healthcare provider in Israel, we identified all adult immunocompromised patients who were eligible to receive Evusheld (the dose used during the study period was 150mg Tixagevimab and 150mg Cilgavimab) on 15-February-2022. Patients with a documentation of a prior SARS-CoV-2 infection were excluded. A total of 703 patients who received Evusheld were propensity score-matched, using a ratio of 1:4, with 2812 patients who have not received Evusheld (control group). Patients were followed through 30-June-2022 for up to 90-days for the first documentation of SARS-CoV-2 infection and COVID-19 related hospitalization. Results: Overall, 72 patients in the Evusheld group and 377 patients in the control group had SARS-CoV-2 infection, reflecting and incidence rate of 4.18 and 5.64 per 100 person-months, respectively. HR was 0.75(95%CI,0.58-0.96) for SARS-CoV-2 infection, and 0.41(0.19-0.89) for COVID-19 related hospitalization in the Evusheld group compared to the control group. The magnitude of relative risks reduction of each outcome was greater in non-obese patients (P for interaction=0.020 and 0.045, respectively). Conclusion: This study suggests that Evusheld (150mg Tixagevimab and 150mg Cilgavimab) is effective in reducing the risk of SARS-CoV-2 infection and COVID-19 hospitalization in immunocompromised patients. The effectiveness of this dose appears to be greater in non-obese patients
Despite that, information about study outcomes and the administration of COVID-19 vaccines, collected prospectively as part of the Israeli MOH COVID-19 database, are considered complete. Information about Evusheld is also closely monitored by CHS and is considered complete. In addition, this retrospective cohort study is observational in nature, hence albeit using propensity score-matched analysis to adjust for confounders, residual confounding remains of concern. Furthermore, undocumented positive home antigen tests and prior asymptomatic SARS-CoV-2 infection is still a concern. However, we assume this might have happened in a minority of immunocompromised patients, a population with a high awareness of their vulnerable health status, and since COVID-19 follow-up services and eligibility for COVID-19 treatments, which might be crucial for these patients, required a documented test. Moreover, SARS-CoV-2 PCR and institutional antigen tests (performed by a healthcare worker and documented) were highly available and free of charge throughout the country. Finally, the outcome measured in the study was laboratory confirmed COVID-19 infection by means of positive PCR or antigen test regardless of symptoms. Conclusions This study suggests that Evusheld is effective in reducing COVID-19 infections and related hospitalizations in immunocompromised adult patients regardless of their vaccination status. Adjusted weight dosing approach is suggested but needs to be further studied. ..
References
-Austin, An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies, Multivariate Behav Res, doi:10.1080/00273171.2011.568786
-Kertes, David, Engel-Zohar, Rosen, Hemo et al., Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality, Clin Infect Dis, doi:10.1093/cid/ciac625
-Lee, Wong, Chai, Lee, Lee et al., Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis, BMJ, doi:10.1136/bmj-2021-068632
-Levin, Ustianowski, Wit, Launay, Avila et al., Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19, N Engl J Med, doi:10.1056/NEJMoa2116620
-Najjar-Debbiny, Gronich, Weber, Khoury, Amar et al., Effectiveness of Paxlovid in Reducing Severe COVID-19 and Mortality in High Risk Patients, Clin Infect Dis, doi:10.1093/cid/ciac443
-Touret, Baronti, Bouzidi, De Lamballerie, In vitro evaluation of therapeutic antibodies against a SARS-CoV-2 Omicron B.1.1.529 isolate, Sci Rep, doi:10.1038/s41598-022-08559-5
-Yanir, Doweck, Shibli, Najjar-Debbiny, Saliba, Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss, JAMA Otolaryngol Head Neck Surg, doi:10.1001/jamaoto.2021.4278
Furer, Eviatar, Zisman, Peleg, Paran et al., Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study, Ann Rheum Dis, doi:10.1136/annrheumdis-2021-220647
Montgomery, Hobbs, Padilla, Arbetter, Templeton et al., Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial, Lancet Respir Med, doi:10.1016/S2213-2600(22)00180-1
{ 'DOI': '10.1093/cid/ciac855', 'ISSN': ['1058-4838', '1537-6591'], 'URL': 'http://dx.doi.org/10.1093/cid/ciac855', 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>Background</jats:title>\n' ' <jats:p>Tixagevimab and Cilgavimab, a combined monoclonal antibody ' '(Evusheld) was granted emergency use authorization for SARS-CoV-2 preexposure prophylaxis in ' 'individuals with moderate to severe immunocompromising condition. In this study we used ' 'population-based real-world data to evaluate the effectiveness of Evusheld in ' 'immunocompromised patients.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Methods</jats:title>\n' ' <jats:p>Using the computerized database of the largest healthcare provider ' 'in Israel, we identified all adult immunocompromised patients who were eligible to receive ' 'Evusheld (the dose used during the study period was 150\u2005mg Tixagevimab and 150\u2005mg ' 'Cilgavimab) on 15-February-2022. Patients with a documentation of a prior SARS-CoV-2 ' 'infection were excluded. A total of 703 patients who received Evusheld were propensity ' 'score-matched, using a ratio of 1:4, with 2812 patients who have not received Evusheld ' '(control group). Patients were followed through 30-June-2022 for up to 90-days for the first ' 'documentation of SARS-CoV-2 infection and COVID-19 related hospitalization.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Results</jats:title>\n' ' <jats:p>Overall, 72 patients in the Evusheld group and 377 patients in the ' 'control group had SARS-CoV-2 infection, reflecting and incidence rate of 4.18 and 5.64 per ' '100 person-months, respectively. HR was 0.75(95%CI,0.58-0.96) for SARS-CoV-2 infection, and ' '0.41(0.19-0.89) for COVID-19 related hospitalization in the Evusheld group compared to the ' 'control group. The magnitude of relative risks reduction of each outcome was greater in ' 'non-obese patients (P for interaction\u2009=\u20090.020 and 0.045, respectively).</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>Conclusion</jats:title>\n' ' <jats:p>This study suggests that Evusheld (150\u2005mg Tixagevimab and ' '150\u2005mg Cilgavimab) is effective in reducing the risk of SARS-CoV-2 infection and ' 'COVID-19 hospitalization in immunocompromised patients. The effectiveness of this dose ' 'appears to be greater in non-obese patients</jats:p>\n' ' </jats:sec>', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7586-3714', 'affiliation': [ { 'name': 'Infection Control and Prevention Unit, Lady Davis Carmel Medical ' 'Center , Haifa , Israel'}, { 'name': 'Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel ' 'Institute of Technology , Haifa , Israel'}], 'authenticated-orcid': False, 'family': 'Najjar-Debbiny', 'given': 'Ronza', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel ' 'Institute of Technology , Haifa , Israel'}, { 'name': 'Department of Community Medicine and Epidemiology, Lady Davis ' 'Carmel Medical Center , Haifa , Israel'}], 'family': 'Gronich', 'given': 'Naomi', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel ' 'Institute of Technology , Haifa , Israel'}, { 'name': 'Infectious Diseases unit, Lady Davis Carmel Medical Center , ' 'Haifa , Israel'}], 'family': 'Weber', 'given': 'Gabriel', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Community Medicine and Epidemiology, Lady Davis ' 'Carmel Medical Center , Haifa , Israel'}, { 'name': 'Statistical Unit, Lady Davis Carmel Medical Center , Haifa , ' 'Israel'}], 'family': 'Stein', 'given': 'Nili', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel ' 'Institute of Technology , Haifa , Israel'}, { 'name': 'Department of Community Medicine and Epidemiology, Lady Davis ' 'Carmel Medical Center , Haifa , Israel'}, { 'name': 'Translational Epidemiology Unit and Research Authority, Lady ' 'Davis Carmel Medical Center , Haifa , Israel'}], 'family': 'Saliba', 'given': 'Walid', 'sequence': 'additional'}], 'container-title': 'Clinical Infectious Diseases', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': { 'date-parts': [[2022, 10, 31]], 'date-time': '2022-10-31T08:00:58Z', 'timestamp': 1667203258000}, 'deposited': { 'date-parts': [[2022, 10, 31]], 'date-time': '2022-10-31T08:00:59Z', 'timestamp': 1667203259000}, 'indexed': {'date-parts': [[2022, 11, 1]], 'date-time': '2022-11-01T04:54:55Z', 'timestamp': 1667278495680}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2022, 10, 31]]}, 'language': 'en', 'license': [ { 'URL': 'https://academic.oup.com/pages/standard-publication-reuse-rights', 'content-version': 'am', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 10, 31]], 'date-time': '2022-10-31T00:00:00Z', 'timestamp': 1667174400000}}], 'link': [ { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac855/46690004/ciac855.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac855/46690004/ciac855.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '286', 'original-title': [], 'prefix': '10.1093', 'published': {'date-parts': [[2022, 10, 31]]}, 'published-online': {'date-parts': [[2022, 10, 31]]}, 'publisher': 'Oxford University Press (OUP)', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac855/6780937'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'subtitle': [], 'title': 'Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis', 'type': 'journal-article'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit